MarketInOut Stock Screener Log In | Sign Up

Replimune Group Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Replimune Group Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,669.44 mln
Float89.16 mln
Earnings Date08/12/2027

Piotroski F-Score

2 / 9
Weak

1-Year Forecast

23.33
Strong upside

Relative Strength

100 / 100
Top performer

Debt / Equity

0.62
Moderate leverage

ROE

-143
Deeply negative

ROA

-80.58
Deeply negative

Business Description

Replimune Group is a biotechnology company focused on developing cancer treatments that use modified viruses to trigger the body's immune system to fight tumors. Founded in 2015 and based in Woburn, Massachusetts, the company has several therapies in development, with its most advanced candidate targeting a broad range of solid tumors. Its pipeline also includes treatments designed to further strengthen the immune response by blocking proteins that would otherwise suppress it or by directly stimulating key immune cells.

Key Fundamentals

EPS-2.79
ROE-143
ROIC-376
ROA-80.58
Interest Cover-22.53
EBITDA, mln-255
EV / EBITDA-6.37
EV / EBIT-6.21

Quote Details

Last 17.61
Change 0.22 (1.27%)
Open 17.49
Volume 3,850,511
Turnover 67,807,504
Average Volume 2,425,733

Financial Ratios

Leverage Ratio1.83
Current Ratio7.11
Price / Book8.15
Price / Tangible Book8.15
Debt / Equity0.62

Financial Strength

Piotroski F-Score 2 / 9
1-Year Target Price23.33
Short Ratio11.50
Short % of Float34.00

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 53.66% 100 / 100   
1 Month 30.93% 98 / 100   
2 Months 81.55% 99 / 100   
6 Months 585% 100 / 100   
1 Year 68.52% 95 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog